Stock Price Quote

NEULAND LABORATORIES LTD.

NSE : NEULANDLABBSE : 524558ISIN CODE : INE794A01010Industry : Pharmaceuticals & DrugsHouse : Private
BSE14268.201767.45 (+14.14 %)
PREV CLOSE ( ) 12500.75
OPEN PRICE ( ) 12749.10
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 11024
TODAY'S LOW / HIGH ( )12393.10 14500.35
52 WK LOW / HIGH ( )3612.05 13600
NSE14247.651748.5 (+13.99 %)
PREV CLOSE( ) 12499.15
OPEN PRICE ( ) 12500.00
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 14247.65 (115)
VOLUME 157171
TODAY'S LOW / HIGH( ) 12343.05 14489.90
52 WK LOW / HIGH ( )3611.1 13630
1D 1M 3M 1Y 3Y 5Y

STOCK SUMMARY

Incorporation Year : 07-01 1984
Management Info
Davuluri Rama Mohan Rao - Chairman Davuluri Saharsh Rao - Managing Director
Registered Office

Address 11th Floor (5th Office Level),Phoenix I V Y Building, Plot No.573 A- I I I,Road No. 82, Jubilee Hills,
Hyderabad,
Telangana-500033

Phone 040-67611600 / 67611700

Email neuland@neulandlabs.com

Website www.neulandlabs.com

Registrars Details
K FIN Technologies Ltd.-(Karvy Fintech Pvt Ltd.)
Karvy Selenium Tower B, Plot 31-32,Gachibowli,Financial District,Nanakramguda,Hyderabad
Listing : BSE, NSE

NEWS

09Oct Neuland Laboratories informs about det
Pursuant to Regulation 39(3) of the SEBI (Listing Obligations & Disc..
01Aug Neuland Laboratories informs about ana
Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosur..
24Jul Neuland Laboratories informs about ear
Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Re..
21Jun Neuland Laboratories informs about los
Neuland Laboratories has informed that the Company has approved issuance..
18Jun Neuland Laboratories informs about inv
Neuland Laboratories has informed that the Company’s management will be..

Financials

in Millions
QTR Jun 24 ANNUAL 24
Net Profit983.392995.96
Gross Profit 1303.09 4007.69
Operating Profit 1286.334744.65
Net Sales 4396.0215585.8

ROLLING FORWARD P/E (EOD)

EVENT CALENDAR

peer group

Abbott India (BSE)
peergroup  28793.10 (1.48%)
M.Cap ( in Cr)61183.33
Divi's Lab (BSE)
peergroup  6141.15 (3.38%)
M.Cap ( in Cr)163028.24
Mankind Pharma (BSE)
peergroup  2794.40 (4.34%)
M.Cap ( in Cr)111956.00
Lupin (BSE)
peergroup  2223.60 (3.18%)
M.Cap ( in Cr)101428.03
NGL Fine-Chem (BSE)
peergroup  2131.00 (3.31%)
M.Cap ( in Cr)1316.54

Shareholding Pattern

MUTUAL FUNDS/UTI 4.07%
NON-INSTITUTION 34.76%
PROMOTERS 32.72%
GOVERNMENT 0.4%
FI/BANKS/INSURANCE 0%
FII 0%

About Neuland Laboratories Ltd.

Neuland Laboratories Ltd. was incorporated in the year 1984. Its today's share price is 14268.2. Its current market capitalisation stands at Rs 18305.94 Cr. In the latest quarter, company has reported Gross Sales of Rs. 15585.81 Cr and Total Income of Rs.15711.25 Cr. The company's management includes Christopher M Cimarusti, Sarada Bhamidipati, Pallavi Joshi Bakhru, Sugata Sircar, Prasad Raghava Menon, Homi Rustam Khusrokhan, Nirmala Murthy, Davuluri Saharsh Rao, Davuluri Sucheth Rao, Davuluri Rama Mohan Rao.

It is listed on the BSE with a BSE Code of 524558 , NSE with an NSE Symbol of NEULANDLAB and ISIN of INE794A01010. It's Registered office is at 11th Floor (5th Office Level),Phoenix I V Y Building, Plot No.573 A- I I I,Road No. 82, Jubilee HillsHyderabad-500033, Telangana. Their Registrars are K FIN Technologies Ltd.-(Karvy Fintech Pvt Ltd.) It's auditors are KS Aiyar & Co, MSKA & Associates, Walker Chandik & Co LLP, Walker Chandiok & Co LLP

© NIRMAL BANG. All rights reserved

Designed , Developed & Content Powered by Accord Fintech Pvt. Ltd.

Open an Account
FOR AFREE *DEMAT & BROKING ACCOUNT

Please fill in the details below

Close X

(Note - You will receive a call from our sales executive)

CLOSE X

RISK DISCLOSURES ON DERIVATIVES

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to ₹ 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source:

1. SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.